On May 28, BeiGene declined 3.21% in regular trading, trading at HK$175.1/share, with trading volume of approximately HK$246 million.
Within the Biotechnology sector where BeiGene belongs, the sector experienced broad-based weakness. Among individual stocks, Innovent Bio down 2.6%, Akeso down 3.3%, 3SBio down 6.22%, PegBio down 3.97%, RemeGen down 3.52%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)